Adaptilens Announces $17.5M Series A Financing

Perceptive Xontogeny Venture Funds Leads Financing to Support Development of Accommodating Intraocular Lens (A-IOL) Through First-in-Human Trials, Paving the Way to Transform Cataract Surgery’s Standard of Care

April 29, 2024

BOSTONApril 29, 2024 — Adaptilens, Inc., a pre-clinical company dedicated to transforming the standard of care for cataract surgery, today announced the closing of a Series A financing round of $17.5 million led by Perceptive Xontogeny Venture Funds (PXV Funds), with additional investments from Pillar VC, 380 Cap, and Accanto Partners. The capital will drive the development of the company’s Accommodating Intraocular Lens (A-IOL), the first and only biomimetic intraocular lens, through first-in-human trials.

The Series A follows an earlier seed round of $1.6 million led by Pillar VC with participation from Accanto Partners and additional awards from the Harvard President’s Innovation Challenge and the Massachusetts Life Sciences Center Initiative for Women Entrepreneurs.

Adaptilens’s mission is to revolutionize cataract surgery by restoring vision to its youthful state. The National Eye Institute expects the number of Americans with cataracts to double by 2050, from 24 million to approximately 50 million. Annually, more than 4 million Americans undergo cataract surgery. The current standard of care for cataract surgery entails replacement of the cataractous lens with a flat, monofocal lens that allows clear vision at either near or far distance, but not both. The Adaptilens A-IOL is a novel, flexible, artificial lens that imitates the human lens by responding to the eye’s natural signal to focus. Restoring clear near, intermediate, and distance vision — unaided by eyeglasses or contact lenses — will provide people with a significant quality of life-enhancing improvement to the current standard of care.

“The young, healthy, human eye is perfectly designed, and its soft, flexible lens is what allows the eye to change power for a full range of vision. Our goal is to provide the growing number of people who need cataract surgery with a biomimetic option that restores youthful vision. This funding is meaningful as it enables our exceptional team to accelerate the development of our best-in-class A-IOL,” commented Liane Clamen, MD, Adaptilens Founder and Chief Executive Officer. “We’re grateful to PXV Funds and our entire investor base for recognizing the transformative potential of Adaptilens.”

“We’re compelled by Adaptilens’s innovative and elegant technology, which lies in their novel A-IOL design and proprietary polymer materials,” said Gianna Hoffman-Luca, PhD, Senior Principal, Venture at Perceptive Advisors and Partner at Xontogeny. “Equally inspiring is the Adaptilens team of experts’ unwavering dedication to developing the best-in-class A-IOL, a game-changing solution for the burgeoning millions of people needing cataract surgery. We’re excited for Adaptilens to join our portfolio of companies and to support them in their next phase of growth from pre-clinical to clinical.”

Adaptilens, Inc. is a privately held, pre-clinical biotech company focused on transforming the standard of care for cataract surgery. A soft and flexible Accommodating Intraocular Lens (A-IOL), the Adaptilens A-IOL is the first and only biomimetic intraocular lens that responds to the eye’s natural signal to focus, thus eliminating the need for eyeglasses or contact lenses. Our mission is to revolutionize cataract surgery by restoring vision to its youthful state.  Adaptilens is based in Boston, Massachusetts. For more information, go to https://adaptilens.com.

The Perceptive Xontogeny Venture Funds (“PXV Funds”) are Perceptive Advisors’ investment vehicles focused on early-stage, private venture investments in life sciences companies. Primary investments for PXV Funds include companies that are seeking a lead investor for private financings, which include both companies that are seeded and incubated at Xontogeny, and companies that are seeded and incubated by other organizations, accelerators and seed investors. The PXV Funds are also open to participating in syndicated private financings as a co-lead or passive investor with other venture capital firms. For more information, visit www.perceptivelife.com.